{
    "elements": [
        {
            "data": {
                "is_heading": 0,
                "text": "Mid & South Essex NHS Foundation Trust"
            },
            "type": "ListItem",
            "sequence_num": 1
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 4,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Ref:"
                    },
                    {
                        "text": "MSEGL-21025"
                    },
                    {
                        "text": "Version:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "05/10/2021"
                    },
                    {
                        "text": "Review date:"
                    },
                    {
                        "text": "04/10/2024"
                    },
                    {
                        "text": "Approved by:"
                    },
                    {
                        "text": "Medicines Assurance Group"
                    },
                    {
                        "text": "24/09/2021"
                    },
                    {
                        "text": "Ratified by:"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "05/10/2021"
                    },
                    {
                        "text": "Author:"
                    },
                    {
                        "text": "Titi Odewumi: Principal Pharmacist Antimicrobials"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Antimicrobial guidelines for the empiric management of diabetic foot infections"
            },
            "type": "ListItem",
            "sequence_num": 3
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction"
            },
            "type": "ListItem",
            "sequence_num": 4
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "Diabetic foot infection is one of the most common complications of diabetes mellitus leading to hospitalization, and amputation of the lower extremity. Neuropathic and/or vascular changes in patients with diabetes mellitus are responsible for the development of chronic foot wounds following minor trauma, or after pressure has caused a breakdown in the integrity of the skin."
            },
            "type": "ListItem",
            "sequence_num": 5
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "Patients with a neuropathic or neuro-ischaemic foot often have little or no pain leading to delayed presentation and diagnosis. Patients may therefore present with an \u201casymptomatic\u201d limb or life threatening infection, often the only clue being deterioration in glycaemic control."
            },
            "type": "ListItem",
            "sequence_num": 6
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "Early assessment of both vascular and sensory functions and accurate diagnosis of the underlying cause is the first step towards a successful treatment, and prevention of limb loss in these patients."
            },
            "type": "ListItem",
            "sequence_num": 7
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.4,
                "text": "The management of the infected diabetic foot can be a complicated process, and includes a number of facets. Initial care of the acute diabetic foot ulcer involves the following points:"
            },
            "type": "ListItem",
            "sequence_num": 8
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Vacuum pump therapy"
            },
            "type": "ListItem",
            "sequence_num": 9
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Total Contact Plaster Casting"
            },
            "type": "ListItem",
            "sequence_num": 10
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Larval therapy"
            },
            "type": "ListItem",
            "sequence_num": 11
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Kerraboot therapy"
            },
            "type": "ListItem",
            "sequence_num": 12
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.5,
                "text": "This guideline aims to promote the consistent care of patients with diabetic foot infections across MSE hospitals."
            },
            "type": "ListItem",
            "sequence_num": 13
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Diabetic foot infections (infected foot ulcers, gangrene and osteomyelitis) are a major cause for admission to hospital. If not treated appropriately, foot infections can lead to septicaemia, amputation and death. A multidisciplinary team approach reduces morbidity and mortality in affected patients."
            },
            "type": "ListItem",
            "sequence_num": 14
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Antimicrobial guidelines for the empiric management of diabetic foot infections/ MSEGL-21025/1.0"
            },
            "type": "ListItem",
            "sequence_num": 15
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "General Considerations"
            },
            "type": "ListItem",
            "sequence_num": 16
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "A good quality microbiological culture is essential for tailoring therapy. Adjust therapy once culture & sensitivity results become available. A culture from deep tissue, obtained by biopsy or curettage after the wound has been cleansed and or debrided is recommended. Superficial swab specimens, usually reflect colonisation, especially of inadequately debrided wounds; thereby providing less accurate results, and potentially misleading."
            },
            "type": "ListItem",
            "sequence_num": 17
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "If response to antibiotics is poor at 48 hours please discuss with Microbiology."
            },
            "type": "ListItem",
            "sequence_num": 18
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "All doses quoted are for normal renal function. Check the recommended antibiotic doses in renal impairment guideline where necessary."
            },
            "type": "ListItem",
            "sequence_num": 19
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.4,
                "text": "Where osteomyelitis is diagnosed, follow local antimicrobial recommendations for osteomyelitis."
            },
            "type": "ListItem",
            "sequence_num": 20
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.5,
                "text": "Disclaimer: Please contact Pharmacy if any drug listed in the guideline is to be used in pregnancy. #Ciprofloxacin---Avoid in pregnancy; #Metronidazole ---- Avoid in early pregnancy, #Doxycycline --- Avoid in pregnancy, #Co-trimoxazole --- Avoid in early pregnancy; contains sulfamethoxazole and trimethoprim. Monitor potassium & renal function whilst patient is on co-trimoxazole, especially if patient is on other potassium sparing drugs."
            },
            "type": "ListItem",
            "sequence_num": 21
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Discontinue co-trimoxazole immediately if patient develops any rash, Co-trimoxazole is associated with a low risk of Steven Johnson syndrome."
            },
            "type": "ListItem",
            "sequence_num": 22
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.6,
                "text": "Antibiotic Traffic Lights"
            },
            "type": "ListItem",
            "sequence_num": 23
        },
        {
            "type": "table",
            "sequence_num": 24,
            "data": {
                "num_rows": 3,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "Suitable in penicillin allergy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Avoid in severe penicillin allergy (e.g. anaphylaxis)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Contra-indicated in penicillin allergy"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 25
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Adult Empiric Antimicrobial Guidelines for diabetic foot infection / MSEGL-21025/1.0"
            },
            "type": "ListItem",
            "sequence_num": 26
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Recommended Antibiotic choices"
            },
            "type": "ListItem",
            "sequence_num": 27
        },
        {
            "type": "table",
            "sequence_num": 28,
            "data": {
                "num_rows": 3,
                "num_cols": 5,
                "table_items": [
                    {
                        "text": "Severity of Infection"
                    },
                    {
                        "text": "Route"
                    },
                    {
                        "text": "First Line Antibiotics"
                    },
                    {
                        "text": "Penicillin Allergic"
                    },
                    {
                        "text": "Duration"
                    },
                    {
                        "text": "MILD 1) Local infection involving only the skin and the subcutaneous tissue, and associated with two or more of the following: Warmth, Pain, Erythema, Tenderness, Induration or Swelling, and Purulent discharge. 2) If erythema, area within >0.5cm to <2cm around the wound and confined to the skin or subcutaneous tissue. 3) No evidence of systemic infection."
                    },
                    {
                        "text": "PO"
                    },
                    {
                        "text": "Flucloxacillin 500mg- 1g QDS"
                    },
                    {
                        "text": "#Doxycycline 100mg BD OR #Clarithromycin 500mg BD"
                    },
                    {
                        "text": "7 - 14 days"
                    },
                    {
                        "text": "MILD/MODERATE Regimen for use in pseudomonas associated infection only (confirmed or suspected as infectious pathogen)."
                    },
                    {
                        "text": "PO (Only use IV if nil by mouth)"
                    },
                    {
                        "text": "#Ciprofloxacin oral 500mg BD / IV 400mg BD + #Metronidazole oral 400mg TDS / IV 500mg TDS"
                    },
                    {
                        "text": "#Ciprofloxacin oral 500mg BD / IV 400mg BD + #Metronidazole oral 400mg TDS / IV 500mg TDS"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 29,
            "data": {
                "num_rows": 3,
                "num_cols": 5,
                "table_items": [
                    {
                        "text": "Severity of Infection"
                    },
                    {
                        "text": "Route"
                    },
                    {
                        "text": "First Line Antibiotics"
                    },
                    {
                        "text": "Penicillin Allergic"
                    },
                    {
                        "text": "Duration"
                    },
                    {
                        "text": "MODERATE No signs of systemic infection. Localized infection as in mild, Plus Erythema > 2cm OR Involving structures deeper than skin and subcutaneous tissues (e.g. Deep abscess, Osteomyelitis, Fasciitis etc)."
                    },
                    {
                        "text": "PO"
                    },
                    {
                        "text": "Co-amoxiclav 625mg TDS +/- Gentamicin 1-3 doses only (dose as per guideline MSEGL-21012)"
                    },
                    {
                        "text": "#Co-trimoxazole 960mg BD + #Metronidazole 400mg TDS If MRSA colonised: #Doxycycline 100mg BD (Tailor therapy once sensitivities confirmed) + #Metronidazole 400mg TDS"
                    },
                    {
                        "text": "7-14 days"
                    },
                    {
                        "text": "SEVERE Local infection as in mild/moderate. PLUS Signs of systemic infection. Any infection accompanied by systemic inflammatory response syndrome (SIRS), manifested by \u2265 2 of the following: 1) Temperature >38\u1d52 or <36\u25e6 Celsius 2) Heart rate >90beats/minute 3) Respiratory rate >20breaths/minute or P\u2090CO2 < 32mmHg 4) WCC >12x109 /L or <4x109/L"
                    },
                    {
                        "text": "IV Review to oral after 48-72hrs if the patient is stable"
                    },
                    {
                        "text": "Flucloxacillin 1g QDS + #Metronidazole 500mg TDS + Gentamicin 1-3 doses only (dose as per guideline MSEGL-21012) OR Ceftriaxone 2grams OD + #Metronidazole 500mg TDS. +/- Gentamicin 1-3 doses only (dose as per guideline MSEGL-21012) OR IV clindamycin 900mg TDS (if gentamicin is contraindicated)."
                    },
                    {
                        "text": "#Co-trimoxazole 960mg BD + #Metronidazole 500mg TDS In Septic shock: Add in Gentamicin 1-3 doses only (dose as per guideline MSEGL-21012) OR IV clindamycin 900mg TDS (if gentamicin is contraindicated)."
                    },
                    {
                        "text": "14 days initially And then review."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 30,
            "data": {
                "num_rows": 3,
                "num_cols": 5,
                "table_items": [
                    {
                        "text": "Severity of Infection"
                    },
                    {
                        "text": "Route"
                    },
                    {
                        "text": "First Line Antibiotics"
                    },
                    {
                        "text": "Penicillin Allergic"
                    },
                    {
                        "text": "Duration"
                    },
                    {
                        "text": "SEVERE Only use this regimen in pseudomonas associated infection (confirmed or suspected as infectious pathogen)"
                    },
                    {
                        "text": "IV"
                    },
                    {
                        "text": "Piperacillin/tazobactam 4.5g TDS +/- Gentamicin 1-3 doses only (dose as per guideline MSEGL-21012) OR IV clindamycin 900mg TDS ( if gentamicin is contraindicated)"
                    },
                    {
                        "text": "#Ciprofloxacin IV 400mg tds Review to oral 750mg BD after 48-72hours + #Metronidazole IV 500mg TDS + In Septic shock: Add in Gentamicin 1-3 doses only (dose as per guidelineMSEGL-21012) OR IV clindamycin 900mg TDS ( if gentamicin is contraindicated"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "SEVERE If MRSA infection suspected or confirmed: Add to the therapy listed above"
                    },
                    {
                        "text": "IV"
                    },
                    {
                        "text": "Vancomycin Or Teicoplanin (Dose as per guidelines)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Antimicrobial guidelines for the empiric management of diabetic foot infections/ MSEGL-21025/1.0"
            },
            "type": "ListItem",
            "sequence_num": 31
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 32
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Adult Empiric Antimicrobial Guidelines for diabetic foot infection / MSEGL-21025/1.0"
            },
            "type": "ListItem",
            "sequence_num": 33
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.1,
                "text": "Caution with use of ciprofloxacin"
            },
            "type": "ListItem",
            "sequence_num": 34
        },
        {
            "data": {
                "is_heading": 0,
                "text": "3.1.1 Due to very rare reports of disabling and potentially long-lasting or irreversible side effects affecting musculoskeletal and nervous systems. There is MHRA warnings which include: stopping treatment at first signs of serious adverse reaction (such as tendonitis), prescribing with special caution in people over 60 years and avoiding co- administration with a corticosteroid."
            },
            "type": "ListItem",
            "sequence_num": 35
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.2,
                "text": "Step down therapy"
            },
            "type": "ListItem",
            "sequence_num": 36
        },
        {
            "data": {
                "is_heading": 0,
                "text": "3.2.1 Treatment options are as for mild or moderate. In addition the following criteria must have been met:"
            },
            "type": "ListItem",
            "sequence_num": 37
        },
        {
            "data": {
                "is_heading": 0,
                "text": "All non-viable tissue and bone sequestra will have been debrided from the wound."
            },
            "type": "ListItem",
            "sequence_num": 38
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Deep tissue samples and bone cultures will help guide antibiotic therapy particularly if MRSA, ESBLs or polymicrobial infections present."
            },
            "type": "ListItem",
            "sequence_num": 39
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Once the wound and patient are stable discharge to the diabetic foot clinic should occur."
            },
            "type": "ListItem",
            "sequence_num": 40
        },
        {
            "data": {
                "is_heading": 0,
                "text": "A switch to oral antimicrobial therapy should take place except under exceptional circumstances e.g. patient NBM."
            },
            "type": "ListItem",
            "sequence_num": 41
        },
        {
            "data": {
                "is_heading": 1,
                "text": "3.2.2 In ESBL related infections oral options are often very limited. Please discuss with Microbiology."
            },
            "type": "ListItem",
            "sequence_num": 42
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "References"
            },
            "type": "ListItem",
            "sequence_num": 43
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Guidelines for UK practice for the diagnosis and management of methicillin- resistant Staphylococcus aureus (MRSA) infections presenting in the community. Journal of Antimicrobial Chemotherapy (2008) 61, 976\u2013994."
            },
            "type": "ListItem",
            "sequence_num": 44
        },
        {
            "data": {
                "is_heading": 0,
                "text": "2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Clinical Infectious Diseases 2012;54(12):132\u2013173."
            },
            "type": "ListItem",
            "sequence_num": 45
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Nice guidance- Diabetic foot problems: prevention and management. Published 26th Aug 2015, Updated 11th October 2019."
            },
            "type": "ListItem",
            "sequence_num": 46
        },
        {
            "data": {
                "is_heading": 0,
                "text": "https://www.nice.org.uk/guidance/ng19/chapter/Recommendations#diabetic-foot- infection. Accessed: 10th June 2021."
            },
            "type": "ListItem",
            "sequence_num": 47
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The use of antibiotics in the diabetic foot. The American Journal of Surgery: Vol 187, Issue 5, Supplement 1, May2004, pages S25-S28."
            },
            "type": "ListItem",
            "sequence_num": 48
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 49
        }
    ]
}